SIVBYXI
Live / Applied — First extension granted (statement of use) (as of 02 Feb 2026)
What this means for you
Not registered yet, but its 13 Feb 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99040791
- Mark type
- Stylized text
- Filed
- 13 Feb 2025
- Published for opposition
- 03 Jun 2025
- Attorney of record
- Heather A. McDonald
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
Owner
- Pfizer Inc., New York, NY, US
- Pfizer Inc., New York, NY, US
Prosecution history
- 03 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Feb 2026 — SOU EXTENSION 1 GRANTED
- 02 Feb 2026 — SOU EXTENSION 1 FILED
- 02 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 24 Jan 2026 — ASSIGNED TO EXAMINER
- 30 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Jun 2025 — PUBLISHED FOR OPPOSITION
- 28 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 May 2025 — ASSIGNED TO EXAMINER
- 13 Feb 2025 — APPLICATION FILING RECEIPT MAILED
- 13 Feb 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 13 Feb 2025 — NEW APPLICATION ENTERED